Clinical Trials Sponsored by CTM Biomedical

Total 2723 results

Synapse Biomedical

Withdrawn

Randomized Study to Investigate the Safety and Performance of Diaphragm Stimulation Coupled With Mechanical Ventilation

Tracheostomy | Ventilator-Induced Lung Injury | Diaphragm Issues

Turkey
Synapse Biomedical

Completed

Humanitarian Device Exemption Post-Approval Study of NeuRx Diaphragm Pacing System for Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS)

United States
Synapse Biomedical

Withdrawn

NeuRx Diaphram Pacing System (DPS) Use in Amyotrophic Lateral Sclerosis (ALS) (PARADIGM)

Amyotrophic Lateral Sclerosis
Synapse Biomedical

Completed

Clinical Study to Investigate Safety and Performance of NeuRx DPS in Patients Undergoing Bilateral Lung Transplantation

Chronic Obstructive Airway Disease

Belgium
Crux Biomedical

Completed

Crux Biomedical Evaluation of the Crux Inferior Vena Cava Filter System 3 ("RETRIEVE 3") (RETRIEVE 3)

Pulmonary Embolism

Belgium
Crux Biomedical

Completed

Crux Biomedical IVC Filter - Evaluation of the Crux Inferior Vena Cava Filter System (Retrieve) (Retrieve)

Pulmonary Embolism
Agen Biomedical

Completed

A Phase II Study to Evaluate the Efficacy of ThromboView® in the Detection of Pulmonary Emboli

Acute Pulmonary Embolism

United States, Canada
Lumen Biomedical

Completed

EPIC US Pivotal Study (EPIC)

Percutaneous Intervention of the Carotid Arteries.

United States
Lumen Biomedical

Completed

EPIC European Study: Use of the FiberNet® Emboli Protection Device in Carotid Artery Stenting

Carotid Artery Stenosis

Germany
MicroPort CRM

Not yet recruiting

PoSt-market Assessment on Safety and Performance of J-sHAPed xFINE Lead (SHAPE)

Bradycardia
MicroPort CRM

Recruiting

Clinical Assessment of Essential Remote Monitoring Functions in Pacemakers (CALLIOPE)

Bradycardia | Remote Monitoring

France, Belgium, Germany, Portugal, Spain, United Kingdom, Austria, Netherlands
MicroPort CRM

Recruiting

Collection of SPOT EGMs And inTra-Cardiac Impedance for Atrio-ventricUlar and inteR-ventricular Delays optimizatioN (SATURN)

Heart Failure

France
CTI BioPharma

Terminated

PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer

COVID-19 | COVID | COVID19

United States
MicroPort CRM

Completed

Safety and Electrical Performances of XFINE Leads (PERSEPOLIS)

Bradycardia

France, Italy, Spain, United Kingdom, Portugal
CTI BioPharma

Terminated

Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia (PAC326)

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States, Canada, France, United Kingdom, Australia, Belgium, Germany, New Zealand, Netherlands, Russian Federation, Hungary, Czechia
CTI BioPharma

Terminated

CT-2584 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Therapy

Prostate Cancer

United States
CTI BioPharma

Withdrawn

CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mL

NSCLC

United States
CTI BioPharma

Withdrawn

Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL

Non-Hodgkin's Lymphoma

United States
CTI BioPharma

Terminated

Polyglutamate Paclitaxel Compared With Gemcitabine or Vinorelbine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

Lung Cancer

United States
MicroPort CRM

Completed

Clinical and Device Functional Assessment of Real World ICD Patients (CARAT)

Arrythmia | Implantable Cardioverter Defibrillator

Spain, United Kingdom, France, Netherlands, Canada, Czechia, Germany, Italy, Switzerland, Portugal, Austria, Slovakia
MicroPort CRM

Unknown

Safety and Electrical Performances Evaluation of Navigo Leads Equipped With IS4 Connector (NAVIGATOR)

Arrythmia, Implatable Cardioverter Defibrillation, Lead

Germany, Spain, France, Italy, Netherlands, Portugal
MicroPort CRM

Completed

Assessment of the MRI Solution: KORA 100 and Beflex Pacing Leads System (IKONE)

Bradycardia

France
MicroPort CRM

Completed

Clinical Assessment of the SonR Algorithm in the PARADYM RF SonR CRT-D by Echocardiography (SonR-ECHO)

Heart Failure

Canada
CTI BioPharma

Terminated

Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma

Lymphoma, Follicular | Lymphoma, Mixed-Cell, Follicular | Lymphoma, Small Cleaved-Cell, Follicular | Lymphoma, Low-Grade

United States
CTI BioPharma

Completed

Phase II CT-2103/Carboplatin in Ovarian Cancer

Ovarian Neoplasm

United States
MicroPort CRM

Recruiting

Post-market Surveillance of Micorport CRM Cardiac Implantable Electronic Devices (PIANO)

Heart Failure | Sudden Cardiac Death | Cardiac Rhythm Disorder

Portugal
MicroPort CRM

Recruiting

Clinical Investigation of ENO/TEO/OTO Pacing System Under MRI Environment (CAPRI)

Bradycardia

France
MicroPort CRM

Active, not recruiting

Assessment of the Axone Micro Quadripolar Lead for Enhanced Cardiac Resynchronization Therapy (ASTRAL-4LV)

Heart Failure | Cardiac Resynchronization Therapy

Netherlands, France, Germany, Spain, Italy, Austria, Portugal
CTI BioPharma

Withdrawn

Pharmacokinetic and Safety Study of Pixantrone in Patients With Metastatic Cancer and Hepatic Impairment (Hepatic)

Metastatic Cancer

United States
CTI BioPharma

Completed

Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib

Primary Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post- Essential Thrombocythemia Myelofibrosis

United States, Spain, United Kingdom, Hungary, Korea, Republic of, France, Italy, Sweden
CTI BioPharma

Withdrawn

Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma

Lymphoma | Leukemia

United States
CTI BioPharma

Terminated

Carboplatin With Either Paclitaxel Poliglumex or Paclitaxel in Treating Women With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Lung Cancer

United States
CTI BioPharma

Terminated

Polyglutamate Paclitaxel Compared With Docetaxel in Treating Patients With Progressive Non-Small Cell Lung Cancer

Lung Cancer

United States
CTI BioPharma

Completed

BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)

Lymphoma, Non-Hodgkin

United States, United Kingdom, France, Italy, India, Germany, Hungary, Argentina, Uruguay, Russian Federation, Bulgaria, Costa Rica, Ecuador, Estonia, Mexico, Panama, Peru, Poland, Romania, Ukraine
CTI BioPharma

Withdrawn

Dose-Escalation Study of Pixantrone Monotherapy in Pediatric Patients With Relapsed or Refractory Cancer

Lymphoma | Solid Tumor (Excluding CNS)

United States
MicroPort CRM

Unknown

Safety and Electrical Performance Evaluation of INVICTA Leads Models Equipped With DF4 Connector (FRIENDS)

Heart Failure | Ventricular Arrythmia | ICD | Lead

Spain, Italy, France, Portugal
MicroPort CRM

Completed

Registry of Sleep Apnea Monitoring and Atrial Fibrillation in Pacemaker Patients (RESPIRE)

Bradycardia

Spain
MicroPort CRM

Completed

EMERALD - AssEssment of CoMorbidities & Atrial ArRhythmiA Burden in DuaL-Chamber PaceD Patients (EMERALD)

Atrial Arrhythmia

United States, Germany, Spain, Denmark, Switzerland, France, Belgium, Australia, Japan, Italy, Canada, Netherlands
CTI BioPharma

Completed

Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma

Lymphoma, Mixed-Cell, Follicular | Lymphoma, Small Cleaved-Cell, Follicular | Lymphoma, Low-Grade | Lymphoma, Small Lymphocytic

United States
CTI BioPharma

Completed

CT-2106 for the Second Line Treatment of Ovarian Cancer

Ovarian Cancer

France, United Kingdom, Italy
BiomediKcal

Completed

Response Evolution Chart

Obesity | Overweight | Adherence, Patient | Motivation

Colombia
CTI BioPharma

Completed

A Trial in Patients With Diffuse Large-B-cell Lymphoma Comparing Pixantrone Against Doxorubicin (RAPID)

Diffuse Large-Cell Lymphoma

United States, Germany, Canada, Italy, France
CTI BioPharma

Completed

Pixantrone (BBR 2778) in Patients With Refractory Acute Myelogenous Leukemia (AML)

Acute Myelogenous Leukemia

United States
MicroPort CRM

Active, not recruiting

Observational Study on Inappropriate Therapies (OSIRIS)

Inappropriate Shocks From Implanted Defibrillator | ICD Replacement or Upgrade

Netherlands, United States, France, Spain, Belgium, Switzerland, Italy, United Kingdom, Germany, Austria, Portugal
MicroPort CRM

Active, not recruiting

Safety and Performance of INVICTA Ventricular DF4 LEADS With Active Fixation-(APOLLO) (APOLLO)

Heart Failure | Ventricular Arrythmia | ICD | Lead

Spain, Portugal
CTI BioPharma

Completed

Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant (PIX-R)

Diffuse Large B-cell Lymphoma | de Novo DLBCL | DLBCL Transformed From Indolent Lymphoma | Follicular Grade 3 Lymphoma

United States, Germany, Italy, United Kingdom, Hungary, France, Spain, Ukraine, Czechia, Austria, Belgium, Bulgaria, Denmark, Poland, Romania, Russian Federation, Slovakia
CTI BioPharma

Terminated

A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy. (PIONEER)

NSCLC

United States, Canada, Bulgaria, Romania, Russian Federation, Ukraine, Mexico, Argentina, Hungary, Poland, United Kingdom
CTI BioPharma

Terminated

Arsenic Trioxide in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
CTI BioPharma

Terminated

Polyglutamate Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

Lung Cancer

Canada, United States
CTI BioPharma

Terminated

Pacritinib Versus Best Available Therapy to Treat Myelofibrosis

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States, Australia, Belgium, Czechia, France, Germany, Hungary, Italy, Netherlands, New Zealand, Russian Federation, United Kingdom

Clinical Trials Sponsored by CTM Biomedical

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Canada

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations